EGFR and non-small cell lung carcinoma: A phase II study in advanced NSCLC patients treated with chemotherapy (CT) or CT and EGFR inhibitors demonstrated that everolimus at a dose of 10 mg/day achieved a response rate of 4.7% and a disease control rate of 47.1% [123].